Meeting News

J&J CEO confirms company’s commitment to ophthalmology

NEWPORT BEACH, Calif. — Johnson & Johnson is “absolutely committed” to ophthalmology and is actively looking at ways to increase its presence in the space due to the large unmet needs of an aging population, Alex Gorsky, CEO of Johnson & Johnson, said here.

In a wide-ranging interview at the OCTANe Ophthalmology Technology Summit with Jim Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, Gorsky was asked if he sees other areas in ophthalmology in which the company could further expand or if he was focused fully on the Abbott Medical Optics acquisition.

“Absolutely, we are just starting,” Gorsky said. “If there is one clear message for J&J that I can share here is that we are absolutely committed to vision and growing this segment and working with you to help patients to frankly create an entire next generation of opportunities in this space. ... We are constantly on the hunt for great new ideas.”

When asked how he sees Johnson & Johnson overcoming the lack of synergy between contact lens care and surgical care, Gorsky said that it all starts with the patient.

“Too often we think in silos. At the end of the day, we believe the patient just wants a really good outcome,” Gorsky said. “We try to take a patient approach to say, what are they thinking about when they have a vision issue that needs to be addressed. In today’s market, patients come in very informed, very engaged. We think there are opportunities there. Second, there are technologies that exist right now that we can use in other areas. And when we think globally outside the U.S., we think that can put a lot of wind in our sails. The goal is to take one plus one and make it 15.” by David W. Mullin

Reference:

Gorsky A. Johnson & Johnson CEO Alex Gorsky interview hosted by Jim Mazzo. Presented at: OCTANe Ophthalmology Technology Summit; June 23-24, 2017; Newport Beach, Calif.

Disclosures: Gorsky reports he is CEO of Johnson & Johnson. Mazzo reports he is global president of ophthalmic devices at Carl Zeiss Meditec.

NEWPORT BEACH, Calif. — Johnson & Johnson is “absolutely committed” to ophthalmology and is actively looking at ways to increase its presence in the space due to the large unmet needs of an aging population, Alex Gorsky, CEO of Johnson & Johnson, said here.

In a wide-ranging interview at the OCTANe Ophthalmology Technology Summit with Jim Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, Gorsky was asked if he sees other areas in ophthalmology in which the company could further expand or if he was focused fully on the Abbott Medical Optics acquisition.

“Absolutely, we are just starting,” Gorsky said. “If there is one clear message for J&J that I can share here is that we are absolutely committed to vision and growing this segment and working with you to help patients to frankly create an entire next generation of opportunities in this space. ... We are constantly on the hunt for great new ideas.”

When asked how he sees Johnson & Johnson overcoming the lack of synergy between contact lens care and surgical care, Gorsky said that it all starts with the patient.

“Too often we think in silos. At the end of the day, we believe the patient just wants a really good outcome,” Gorsky said. “We try to take a patient approach to say, what are they thinking about when they have a vision issue that needs to be addressed. In today’s market, patients come in very informed, very engaged. We think there are opportunities there. Second, there are technologies that exist right now that we can use in other areas. And when we think globally outside the U.S., we think that can put a lot of wind in our sails. The goal is to take one plus one and make it 15.” by David W. Mullin

Reference:

Gorsky A. Johnson & Johnson CEO Alex Gorsky interview hosted by Jim Mazzo. Presented at: OCTANe Ophthalmology Technology Summit; June 23-24, 2017; Newport Beach, Calif.

Disclosures: Gorsky reports he is CEO of Johnson & Johnson. Mazzo reports he is global president of ophthalmic devices at Carl Zeiss Meditec.

    See more from OCTANe Ophthalmology Technology Summit